Bluebird Bio on brink of turning science fiction into reality, European head says

6 November 2017

Where US biotech bluebird bio (Nasdaq: BLUE) is concerned, comparisons can easily be drawn with the gene therapy field as a whole.

There has been a lot of promise and excitement among the scientific and investor communities over a period of decades, but for the most part, patients are still waiting for the products that will change or save their lives.

Since Bluebird has been around since 1992 and claims to be the leader of the gene therapy revolution, it is not surprising that questions are starting to arise on when its pipeline will actually deliver the products that it has long promised for patients with severe genetic and rare diseases and cancer, especially when other big names in this space have scored US approvals for their gene therapies in recent months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK